Judge declines to dismiss Moderna patent infringement case involving COVID-19 vaccine
Arbutus Biopharma and Genevant Sciences sued Moderna in 2022.
The Facts Inside Our Reporter’s Notebook
U.S. District Judge Mitchell Goldberg this week rejected a request from biomedical company Moderna to dismiss a patent infringement case concerning two companies that have alleged Moderna's COVID-19 vaccine used patented technology. Arbutus Biopharma and Genevant Sciences sued Moderna in 2022, the Epoch Times reported.
Moderna's motion to dismiss followed a filing from the federal government arguing that it ought to face the suit rather than the company. The courts previously rejected a separate bid from Moderna for dismissal.
Goldberg contended that Moderna had failed to establish that its development of the vaccine occurred "for the Government" and "with the authorization and consent of the Government" and therefore rejected the claim.
While Moderna denies the allegations from Arbutus and Genevant, it recently acknowledged that federal researchers with the National Institute of Allergy and Infectious Diseases (NIAID) contributed to its development and agreed to paying a $400 million "catch up" payment to the agency and to pay modest royalties on future sales of its vaccine.
Ben Whedon is an editor and reporter for Just the News. Follow him on Twitter.
Just News, No Noise
- DHS heavily redacted Disinformation Board emails despite claiming agency had nothing to hide
- Two years later, Jan. 6 video footage raises new questions about police and prosecutors
- Durham bombshell: Prosecutor unveils smoking gun FBI text message, 'joint venture' to smear Trump
- Accused GOP Rep: J6 panel knowingly peddled false 'political narrative' of Jan. 5 recon of Capitol
- Senate votes 66-30 to repeal military force authorizations used to fight Iraq